Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Март 7, 2025
Background The escalating global cancer burden, projected to reach 35 million new cases by 2050, underscores the urgent need for innovative biomarkers improve treatment efficacy and patient outcomes. TMED family, particularly TMED9, has garnered attention its involvement in progression; however, comprehensive role across various types remains poorly understood. Methods Utilizing multi-omics data, we analyzed expression pattern, prognostic significance, genomic alterations, immunological features of TMED9 types. Through vitro experiments, paid special glioma, especially correlation with glioma cell migration invasion behavior. Results Our findings reveal that is significantly overexpressed tumor tissues associated poor prognosis cancers such as glioblastoma lower-grade gliomas. Genetic analysis shows mutations predominantly kidney renal clear carcinoma, linked chromosomal instability. Immunological indicates correlates positively immune infiltration, macrophages, suggesting promoting immunity. Furthermore, was negatively correlated stemness, indicating potential influence on chemotherapy resistance. Knockdown led reduced lines. Conclusions positions a critical player progression modulation, Elevated poorer outcomes may serve marker therapeutic target. Future research should focus elucidating TMED9’s mechanistic pathways validating clinical settings enhance strategies.
Язык: Английский